This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Windtree Therapeutics’s 8K filing here.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.
Featured Articles
- Five stocks we like better than Windtree Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What Are the U.K. Market Holidays? How to Invest and Trade
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Which Wall Street Analysts are the Most Accurate?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
